Diagnostic accuracy of prostate needle biopsy

Current Urology Reports

Volumn 3, Issue 3, 2002, Pages 215-221

  Donahue, Timothy ^a   Moul, Judd ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Cancer Detection Rate; Prostate Biopsy; Prostate Cancer; Prostate Cancer Detection; Repeat Biopsy

Indexed keywords

HUMAN; MALE; METHODOLOGY; NEEDLE BIOPSY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REPRODUCIBILITY; REVIEW; STATISTICS;

BIOPSY, NEEDLE; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 0036616946     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-002-0067-7     Document Type: Article

References (47)

1. Ries LAG, Eisner MP, Kosary CL, et al. eds:, SEER Cancer Statistics Review 1973–1997. Bethesda: National Cancer Institute; 2000.
2. American Urological Association: Prostate-specific antigen (PSA) best practice policy. Oncology (Huntingt) 2000, 14:267–272.
3. Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997, 277:1452–1555. DOI: 10.1001/jama.277.18.1452
4. Renfer LG, Schow D, Thompson IM, et al.: Is ultrasound guidance necessary for transrectal prostate biopsy? J Urol 1995, 154:1390–1391. DOI: 10.1016/S0022-5347(01)66873-3
5. Devonec M, Fendler JP, Monsallier M, et al.: The significance of the prostatic hypoechoic area: results in 226 ultrasonically guided prostatic biopsies. J Urol 1990, 143:316–319. This article defines the ultrasound characteristics of the prostate gland and prostate cancer.
6. Hodge KK, McNeal JE, Terris MK, et al.: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989, 142:71–74. This is a seminal reference on sextant biopsies, which defined the standard for transrectal core biopsies of the prostate.
7. Catalona WJ, Smith DS, Ratliff TL, et al.: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324:1156–1161. DOI: 10.1056/NEJM199104253241702
8. Brawer MK, Chetner MP, Beatie J, et al.: Screening for prostatic carcinoma with prostate-specific antigen. J Urol 1992, 147:841–845.
9. Keetch DW, Catalona WJ, Smith DS: Serial prostatic biopsy in men with persistently elevated serum prostate-specific antigen levels. J Urol 1994, 151:1571–1574.
10. Ellis WJ, Brawer MK: Repeat prostate needle biopsy: who needs it? J Urol 1995, 153:1496–1498. DOI: 10.1016/S0022-5347(01)67444-5
11. Fleshner NE, Fair WR: Indications for transition zone biopsy in the detection of prostatic carcinoma. J Urol 1997, 157:556–558. DOI: 10.1016/S0022-5347(01)65200-5
12. Uzzo RG, Wei JT, Waldbaum RS, et al.: The influence of prostatic size on cancer detection. Urology 1995, 46:831–836. DOI: 10.1016/S0090-4295(99)80353-7
13. Karakiewicz PI, Bazinet M, Aprikian AG, et al.: Outcome of sextant biopsy according to gland volume. Urology 1997, 49:55–59. DOI: 10.1016/S0090-4295(96)00360-3
14. Stamey TA: Making the most out of six systematic sextant biopsies. Urology 1995, 45:2–12. DOI: 10.1016/S0090-4295(95)96168-2
15. Eskew LA, Bare RL, McCullough DL, et al.: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997, 157:199–202. This article introduced the concept of extended biopsy protocols. DOI: 10.1016/S0022-5347(01)65322-9
16. Chang JJ, Shinohara K, Bhargava V, et al.: Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998, 160:2111–2114. DOI: 10.1016/S0022-5347(01)62254-7
17. Bauer JJ, Zeng J, Weir J, et al.: Three-dimensional computersimulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer. Urology 1999, 53:961–967. DOI: 10.1016/S0090-4295(99)00068-0
18. Bauer JJ, Zeng J, Zhang W, et al.: Lateral biopsies added to the traditional sextant prostate biopsy pattern increases the detection rate of prostate cancer. Prostate Cancer Prostatic Dis 2000, 3:43–46. DOI: 10.1038/sj.pcan.4500397
19. Babaian RJ, Toi A, Kamoi K, et al.: A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000, 163:152–157. DOI: 10.1016/S0022-5347(05)67993-1
20. Levine MA, Ittman M, Melamed J, et al.: Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for detection of prostate cancer. J Urol 1998, 159:471–475. DOI: 10.1016/S0022-5347(01)63951-X
21. Arnold PM, Niemann TH, Bahnson RR: Extended sector biopsy for detection of carcinoma of the prostate. Urol Oncol 2001, 6:91–93. DOI: 10.1016/S1078-1439(00)00111-3
22. Naughton CK, Ornstein DK, Smith DS, et al.: Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol 2000, 163:168–171. DOI: 10.1016/S0022-5347(05)67996-7
23. Naughton CK, Miller DC, Mager DE, et al.: A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 2000, 164:388–392. DOI: 10.1016/S0022-5347(05)67367-3
24. Presti JC, Chang JJ, Bhargava V, et al.: The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000, 163:163–166. DOI: 10.1016/S0022-5347(05)67995-5
25. Gore JL, Shariat SF, Miles BJ, et al.: Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001, 165:1554–1559. DOI: 10.1016/S0022-5347(05)66347-1
26. Ravery V, Goldblatt L, Royer B, et al.: Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 2000, 164:393–396. DOI: 10.1016/S0022-5347(05)67368-5
27. Epstein JI, Walsh PC, Carter HB: Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 2001, 57:1112–1116. DOI: 10.1016/S0090-4295(01)00979-7
28. Djavan B, Waldert M, Zlotta A, et al.: Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001, 166:856–860. DOI: 10.1016/S0022-5347(05)65851-X
29. O’Dowd GJ, Miller MC, Orozco R, et al.: Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000, 55:553–559. DOI: 10.1016/S0090-4295(00)00447-7
30. Fowler JE, Bigler SA, Miles D, et al.: Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol 2000, 163:813–818. DOI: 10.1016/S0022-5347(05)67810-X
31. Borboroglu PG, Comer SW, Riffenburgh RH, et al.: Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000, 163:158–162. DOI: 10.1016/S0022-5347(05)67994-3
32. Park S, Shinohara K, Grossfeld GD, et al.: Prostate cancer detection in men with prior high grade intraepithelial neoplasia or atypical prostate biopsy. J Urol 2001, 165:1409–1414. DOI: 10.1016/S0022-5347(05)66318-5
33. Borboroglu PG, Sur RL, Roberts JL, et al.: Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol 2001, 166:866–870. DOI: 10.1016/S0022-5347(05)65853-3
34. Allen EA, Kahane H, Epstein JI: Repeat biopsy strategies for men with atypical diagnoses on initial needle biopsy. Urology 1998, 52:803–807. DOI: 10.1016/S0090-4295(98)00291-X
35. Liu IJ, Macy M, Lai Y-H, et al.: Critical evaluation of the current indications for transition zone biopsies. Urology 2001, 57:1117–1120. DOI: 10.1016/S0090-4295(01)00944-X
36. Vanasupa BP, Miller TA, Schwartz BF: Diagnosis of prostate adenocarcinoma using transurethral resection of the prostate after multiple negative transrectal biopsies and persistently elevated prostate-specific antigen level. Urology 2000, 56:1056xi-1056xii. DOI: 10.1016/S0090-4295(00)00810-4
37. Stamey TA: Editorial Comment: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997, 157:202–203. DOI: 10.1097/00005392-199701000-00060
38. Moul JW: Prostate biopsy quantitative histology as a staging and prognostic factor. J Urol 2002, 167:526–527. DOI: 10.1016/S0022-5347(01)69078-5
39. Freedland SJ, Csathy GS, Dorey F, et al.: Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate-specific antigen or Gleason score. J Urol 2002, 167:516–520. DOI: 10.1016/S0022-5347(01)69076-1
40. Conrad S, Graefen M, Pichlmeier U, et al.: Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostate cancer. J Urol 2002, 167:521–525. DOI: 10.1016/S0022-5347(01)69077-3
41. Naughton CK, Smith DS, Humphrey PA, et al.: Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 1998, 52:808–813. DOI: 10.1016/S0090-4295(98)00344-6
42. Yang XJ, Lecksell K, Potter SR, et al.: Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy. Urology 1999, 54:528–532. DOI: 10.1016/S0090-4295(99)00166-1
43. de la Taille A, Katz A, Bagiella E, et al.: Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999, 54:1039–1043. DOI: 10.1016/S0090-4295(99)00350-7
44. Sebo TJ, Bock BJ, Cheville JC, et al.: The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 2000, 163:174–178. DOI: 10.1016/S0022-5347(05)67998-0
45. Egevad L, Norberg M, Mattson S, et al.: Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy. Urology 1998, 52:653–658. DOI: 10.1016/S0090-4295(98)00221-0
46. Sanwick JM, Dalkin BL, Nagle RB: Accuracy of prostate needle biopsy in predicting extracapsular tumor extension at radical retropubic prostatectomy: application in selecting patients for nerve-sparing surgery. Urology 1998, 52:814–819. DOI: 10.1016/S0090-4295(98)00399-9
47. D’Amico AV, Whittington R, Malkowicz SB, et al.: Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 2000, 18:3240–3246. A very useful reference for counseling patients, and for use in day-today practice.